YIH
RXDX

Y-Intercept (HK)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Y-Intercept (HK)’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,623
Closed -$619K – 1655
2022
Q4 		$619K Buy
+5,623
New +$365K 0.09% 350

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Y-Intercept (HK)'s RXDX Position: Q1 2023 in Review

Y-Intercept (HK) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2023, closing a stake of 5,623 shares — an estimated $619K sold.

Y-Intercept (HK) first reported a position in RXDX in Q4 2022 and held it in 1 quarter. The position peaked at $619K in Q4 2022. 219 funds tracked by Wall St. Rank hold RXDX as of Q1 2023.

  • Y-Intercept (HK) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 5,623 Prometheus Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $619K.
  • Y-Intercept (HK) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s Prometheus Biosciences, Inc. Common Stock position peaked at $619K in Q4 2022.
  • 219 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2023.

Based on Y-Intercept (HK)'s 13F filing for Q1 2023, filed 9 May 2023.